David Eichenbaum, MD, and Ferhina Ali, MD, MPH, discuss how the introduction of complement inhibitor therapies has transformed geographic atrophy management from a “come back in a year” conversation to active treatment discussions focused on slowing disease progression, with emphasis on early intervention, patient selection, and the evolving approaches to integrating these first-in-class treatments into clinical practice.
Judy Kim, MD and Peter Kaiser, MD present a comprehensive discussion on evolving therapeutic strategies for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), addressing barriers like step therapy, discuss the potential use of biosimilars, along with the efficacy and safety of newer therapies such as faricimab and high-dose aflibercept.
Video Series in available therapies and some that are still in development as well as practical considerations in treatment of wet AMD during the post-pandemic era.
